Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27136388 | 0.86 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2MAPTGAANPC1 | |
| SCHEMBL5261314 | 0.86 | SMN1; SMN2 (0.68) | ALDH1A1SMN1; SMN2MAPTGAANPC1 | |
| SCHEMBL31078542 | 0.85 | SMN1; SMN2 (0.62) | ALDH1A1SMN1; SMN2MAPTGAANPC1 | |
| SCHEMBL3594939 | 0.85 | SMN1; SMN2 (0.62) | ALDH1A1SMN1; SMN2MAPTGAANPC1 | |
| SCHEMBL2832021 | 0.84 | SMN1; SMN2 (0.70) | ALDH1A1SMN1; SMN2MAPTGAANPC1 | |
| SCHEMBL25015138 | 0.83 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2MAPTGAANPC1 | |
| SCHEMBL27136664 | 0.83 | SMN1; SMN2 (0.73) | ALDH1A1SMN1; SMN2MAPTGAANPC1 | |
| SCHEMBL2010247 | 0.83 | SMN1; SMN2 (0.69) | ALDH1A1SMN1; SMN2MAPTGAANPC1 | |
| SCHEMBL469448 | 0.82 | SMN1; SMN2 (0.71) | ALDH1A1SMN1; SMN2MAPTGAANPC1 | |
| SCHEMBL1066371 | 0.82 | SMN1; SMN2 (0.68) | ALDH1A1SMN1; SMN2MAPTGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3653618-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-01-08 | — | — | EP | disclosed |
| EP-3653618-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-05-20 | — | — | EP | disclosed |
| EP-3653618-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-05-20 | — | — | EP | disclosed |
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | disclosed |
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | disclosed |
| EP-2758388-B1 | NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-02-21 | — | — | EP | disclosed |
| EP-2758388-B1 | NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-02-21 | — | — | EP | disclosed |
| EP-2701512-B1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2701512-B1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2861071-B1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-03-15 | — | — | EP | disclosed |
| US-8173813-B2 | selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants | NEURAXON, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| CN-101679397-A | Quinolone and tetrahydroquinoline having NOS inhibitory activity and related compounds | NEURAXON INC | 2010-03-24 | — | — | CN | disclosed |
| EP-2139886-A1 | QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2010-01-06 | — | — | EP | disclosed |
| WO-2009106534-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106534-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| WO-2008116308-A1 | QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116308-A1 | QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-09-25 | — | — | US | disclosed |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-09-25 | — | — | US | disclosed |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS1, NOS2, NOS3 | ALDH1A1 1027/4885SMN1; SMN2 1798/4885MAPT 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.